Cocrystal Pharma Presents Positive Preclinical Data for CC-42344 at the Options X for the Control of Influenza Conference
September 03, 2019 08:05 ET
|
Cocrystal Pharma, Inc.
- CC-42344 showed broad spectrum activity, excellent anti-influenza activity (EC50 <1 nM), and a strong synergistic effect with approved influenza antivirals - - Preclinical study...
Cocrystal Pharma Announces Abstract Accepted for Oral Presentation at the ISIRV: Options X for the Control of Influenza Conference
August 21, 2019 08:05 ET
|
Cocrystal Pharma, Inc.
BOTHELL, WA, Aug. 21, 2019 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ: COCP), (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel...